ENANTA PHARMACEUTICALS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ENANTA PHARMACEUTICALS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Sep 30, 2017 | $75.93M | Dec 11, 2017 |
| FY2017 | Jun 30, 2017 | $7.51M | Dec 11, 2017 |
| FY2017 | Mar 31, 2017 | $8.96M | Dec 11, 2017 |
| FY2017 | Dec 31, 2016 | $10.42M | Dec 11, 2017 |
| FY2017 | Sep 30, 2016 | $12.84M | Dec 11, 2017 |
| FY2017 | Jun 30, 2016 | $13.98M | Dec 11, 2017 |
| FY2017 | Mar 31, 2016 | $13.00M | Dec 11, 2017 |
| FY2017 | Dec 31, 2015 | $48.45M | Dec 11, 2017 |
| FY2016 | Sep 30, 2015 | $14.42M | Dec 9, 2016 |
| FY2016 | Jun 30, 2015 | $11.60M | Dec 9, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $65.32M | Nov 19, 2025 |
| FY2025 | Sep 30, 2024 | $67.64M | Nov 19, 2025 |
| FY2025 | Sep 30, 2023 | $79.20M | Nov 19, 2025 |
| FY2024 | Sep 30, 2022 | $86.16M | Nov 27, 2024 |
| FY2023 | Sep 30, 2021 | $97.07M | Nov 22, 2023 |
| FY2020 | Sep 30, 2020 | $23.63M | Nov 25, 2020 |
| FY2020 | Jun 30, 2020 | $18.65M | Nov 25, 2020 |
| FY2020 | Mar 31, 2020 | $27.62M | Nov 25, 2020 |
| FY2020 | Dec 31, 2019 | $52.57M | Nov 25, 2020 |
| FY2020 | Sep 30, 2019 | $51.31M | Nov 25, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($81.89M) | Nov 19, 2025 |
| FY2025 | Sep 30, 2024 | ($116.05M) | Nov 19, 2025 |
| FY2025 | Sep 30, 2023 | ($133.82M) | Nov 19, 2025 |
| FY2024 | Sep 30, 2022 | ($121.76M) | Nov 27, 2024 |
| FY2023 | Sep 30, 2021 | ($79.00M) | Nov 22, 2023 |
| FY2020 | Sep 30, 2020 | ($29.34M) | Nov 25, 2020 |
| FY2020 | Jun 30, 2020 | ($14.27M) | Nov 25, 2020 |
| FY2020 | Mar 31, 2020 | ($6.01M) | Nov 25, 2020 |
| FY2020 | Dec 31, 2019 | $13.44M | Nov 25, 2020 |
| FY2020 | Sep 30, 2019 | $9.19M | Nov 25, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($85.35M) | Nov 19, 2025 |
| FY2025 | Sep 30, 2024 | ($121.69M) | Nov 19, 2025 |
| FY2025 | Sep 30, 2023 | ($137.21M) | Nov 19, 2025 |
| FY2024 | Sep 30, 2022 | ($123.84M) | Nov 27, 2024 |
| FY2023 | Sep 30, 2021 | ($109.57M) | Nov 22, 2023 |
| FY2022 | Sep 30, 2020 | ($41.64M) | Nov 23, 2022 |
| FY2021 | Sep 30, 2019 | $36.74M | Nov 24, 2021 |
| FY2020 | Sep 30, 2018 | $88.33M | Nov 25, 2020 |
| FY2019 | Sep 30, 2017 | $24.61M | Nov 27, 2019 |
| FY2018 | Sep 30, 2016 | $30.84M | Nov 29, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $106.74M | Nov 19, 2025 |
| FY2025 | Sep 30, 2024 | $131.48M | Nov 19, 2025 |
| FY2025 | Sep 30, 2023 | $163.52M | Nov 19, 2025 |
| FY2024 | Sep 30, 2022 | $164.52M | Nov 27, 2024 |
| FY2023 | Sep 30, 2021 | $174.11M | Nov 22, 2023 |
| FY2022 | Sep 30, 2020 | $136.76M | Nov 23, 2022 |
| FY2021 | Sep 30, 2019 | $142.21M | Nov 24, 2021 |
| FY2020 | Sep 30, 2018 | $94.86M | Nov 25, 2020 |
| FY2019 | Sep 30, 2017 | $57.45M | Nov 27, 2019 |
| FY2018 | Sep 30, 2016 | $40.46M | Nov 29, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($19.27M) | Nov 19, 2025 |
| FY2025 | Sep 30, 2024 | ($78.76M) | Nov 19, 2025 |
| FY2025 | Sep 30, 2023 | ($103.15M) | Nov 19, 2025 |
| FY2024 | Sep 30, 2022 | ($84.78M) | Nov 27, 2024 |
| FY2023 | Sep 30, 2021 | ($70.00M) | Nov 22, 2023 |
| FY2022 | Sep 30, 2020 | $7.09M | Nov 23, 2022 |
| FY2021 | Sep 30, 2019 | $71.42M | Nov 24, 2021 |
| FY2020 | Sep 30, 2018 | $29.22M | Nov 25, 2020 |
| FY2019 | Sep 30, 2017 | $52.65M | Nov 27, 2019 |
| FY2018 | Sep 30, 2016 | $35.81M | Nov 29, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $12.90M | Nov 19, 2025 |
| FY2025 | Sep 30, 2024 | $17.95M | Nov 19, 2025 |
| FY2025 | Sep 30, 2023 | $9.06M | Nov 19, 2025 |
| FY2024 | Sep 30, 2022 | $2.13M | Nov 27, 2024 |
| FY2023 | Sep 30, 2021 | $750.0K | Nov 22, 2023 |
| FY2022 | Sep 30, 2020 | $1.45M | Nov 23, 2022 |
| FY2021 | Sep 30, 2019 | $5.42M | Nov 24, 2021 |
| FY2020 | Sep 30, 2018 | $2.98M | Nov 25, 2020 |
| FY2019 | Sep 30, 2017 | $2.51M | Nov 27, 2019 |
| FY2018 | Sep 30, 2016 | $4.74M | Nov 29, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $280.73M | Nov 19, 2025 |
| FY2025 | Sep 30, 2024 | $376.65M | Nov 19, 2025 |
| FY2024 | Sep 30, 2023 | $462.28M | Nov 27, 2024 |
| FY2023 | Sep 30, 2022 | $375.41M | Nov 22, 2023 |
| FY2022 | Sep 30, 2021 | $438.79M | Nov 23, 2022 |
| FY2021 | Sep 30, 2020 | $486.13M | Nov 24, 2021 |
| FY2020 | Sep 30, 2019 | $489.83M | Nov 25, 2020 |
| FY2019 | Sep 30, 2018 | $414.23M | Nov 27, 2019 |
| FY2018 | Sep 30, 2017 | $326.64M | Nov 29, 2018 |
| FY2017 | Sep 30, 2016 | $281.28M | Dec 11, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $216.02M | Nov 19, 2025 |
| FY2025 | Sep 30, 2024 | $247.84M | Nov 19, 2025 |
| FY2024 | Sep 30, 2023 | $245.54M | Nov 27, 2024 |
| FY2023 | Sep 30, 2022 | $54.08M | Nov 22, 2023 |
| FY2022 | Sep 30, 2021 | $39.36M | Nov 23, 2022 |
| FY2021 | Sep 30, 2020 | $30.55M | Nov 24, 2021 |
| FY2020 | Sep 30, 2019 | $27.34M | Nov 25, 2020 |
| FY2019 | Sep 30, 2018 | $20.55M | Nov 27, 2019 |
| FY2018 | Sep 30, 2017 | $24.96M | Nov 29, 2018 |
| FY2017 | Sep 30, 2016 | $11.34M | Dec 11, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $64.72M | Nov 19, 2025 |
| FY2025 | Sep 30, 2024 | $128.81M | Nov 19, 2025 |
| FY2025 | Sep 30, 2023 | $216.74M | Nov 19, 2025 |
| FY2025 | Sep 30, 2022 | $321.33M | Nov 19, 2025 |
| FY2024 | Sep 30, 2021 | $399.43M | Nov 27, 2024 |
| FY2023 | Sep 30, 2020 | $455.58M | Nov 22, 2023 |
| FY2022 | Sep 30, 2019 | $462.49M | Nov 23, 2022 |
| FY2021 | Sep 30, 2018 | $393.68M | Nov 24, 2021 |
| FY2020 | Sep 30, 2017 | $301.68M | Nov 25, 2020 |
| FY2019 | Sep 30, 2016 | $269.94M | Nov 27, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($404.93M) | Nov 19, 2025 |
| FY2025 | Sep 30, 2024 | ($323.04M) | Nov 19, 2025 |
| FY2024 | Sep 30, 2023 | ($207.00M) | Nov 27, 2024 |
| FY2023 | Sep 30, 2022 | ($73.18M) | Nov 22, 2023 |
| FY2022 | Sep 30, 2021 | $48.58M | Nov 23, 2022 |
| FY2021 | Sep 30, 2020 | $127.57M | Nov 24, 2021 |
| FY2020 | Sep 30, 2019 | $163.74M | Nov 25, 2020 |
| FY2019 | Sep 30, 2018 | $117.36M | Nov 27, 2019 |
| FY2018 | Sep 30, 2017 | $45.36M | Nov 29, 2018 |
| FY2017 | Sep 30, 2016 | $27.65M | Dec 11, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $32.30M | Nov 19, 2025 |
| FY2025 | Sep 30, 2024 | $37.23M | Nov 19, 2025 |
| FY2024 | Sep 30, 2023 | $85.39M | Nov 27, 2024 |
| FY2023 | Sep 30, 2022 | $43.99M | Nov 22, 2023 |
| FY2022 | Sep 30, 2021 | $57.21M | Nov 23, 2022 |
| FY2021 | Sep 30, 2020 | $87.13M | Nov 24, 2021 |
| FY2020 | Sep 30, 2019 | $51.23M | Nov 25, 2020 |
| FY2019 | Sep 30, 2018 | $63.90M | Nov 27, 2019 |
| FY2018 | Sep 30, 2017 | $65.68M | Nov 29, 2018 |
| FY2018 | Sep 30, 2016 | $16.58M | Nov 29, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | (3) | Nov 19, 2025 |
| FY2025 | Sep 30, 2024 | (5) | Nov 19, 2025 |
| FY2025 | Sep 30, 2023 | (6) | Nov 19, 2025 |
| FY2024 | Sep 30, 2022 | (5) | Nov 27, 2024 |
| FY2023 | Sep 30, 2021 | (3) | Nov 22, 2023 |
| FY2020 | Sep 30, 2020 | (1) | Nov 25, 2020 |
| FY2020 | Jun 30, 2020 | 0 | Nov 25, 2020 |
| FY2020 | Mar 31, 2020 | 0 | Nov 25, 2020 |
| FY2020 | Dec 31, 2019 | 0 | Nov 25, 2020 |
| FY2020 | Sep 30, 2019 | 0 | Nov 25, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | (3) | Nov 19, 2025 |
| FY2025 | Sep 30, 2024 | (5) | Nov 19, 2025 |
| FY2025 | Sep 30, 2023 | (6) | Nov 19, 2025 |
| FY2024 | Sep 30, 2022 | (5) | Nov 27, 2024 |
| FY2023 | Sep 30, 2021 | (3) | Nov 22, 2023 |
| FY2020 | Sep 30, 2020 | (1) | Nov 25, 2020 |
| FY2020 | Jun 30, 2020 | 0 | Nov 25, 2020 |
| FY2020 | Mar 31, 2020 | 0 | Nov 25, 2020 |
| FY2020 | Dec 31, 2019 | 0 | Nov 25, 2020 |
| FY2020 | Sep 30, 2019 | 0 | Nov 25, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 21.39M | Nov 19, 2025 |
| FY2025 | Sep 30, 2024 | 21.19M | Nov 19, 2025 |
| FY2024 | Sep 30, 2023 | 21.06M | Nov 27, 2024 |
| FY2023 | Sep 30, 2022 | 20.79M | Nov 22, 2023 |
| FY2022 | Sep 30, 2021 | 20.24M | Nov 23, 2022 |
| FY2021 | Sep 30, 2020 | 20.08M | Nov 24, 2021 |
| FY2020 | Sep 30, 2019 | 19.70M | Nov 25, 2020 |
| FY2019 | Sep 30, 2018 | 19.40M | Nov 27, 2019 |
| FY2018 | Sep 30, 2017 | 19.12M | Nov 29, 2018 |
| FY2017 | Sep 30, 2016 | 19.04M | Dec 11, 2017 |